Poster-Neurophysiology; Neuropsychology and Neuropsychiatry
October 25, 2021
Stability of the Gut Microbiota in Persons with Pediatric-Onset Multiple Sclerosis and Related Demyelinating Diseases
Background: Little is known about the stability of the gut microbiota in multiple sclerosis (MS) over time. Objectives: To determine if the...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study
Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study
Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years
Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...
Poster-Disease-modifying Therapy
October 25, 2021
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...
Poster-Disease-modifying Therapy
October 25, 2021
Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...